Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.50 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 6/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9780135 | 0.71 | GPR3 (0.43) | GPR3LIMK1CDK5CDK5R1MAPT | |
| Dibenzothiophene SCHEMBL13294 | 0.69 | GPR3 (1.00) | GPR3LIMK1MAPTALDH1A1RAB9A | |
| Dibenzothiophene SCHEMBL30167635 | 0.69 | GPR3 (1.00) | GPR3LIMK1MAPTALDH1A1RAB9A | |
| Dibenzothiophene SCHEMBL14659543 | 0.69 | GPR3 (1.00) | GPR3LIMK1MAPTALDH1A1RAB9A | |
| Dibenzothiophene SCHEMBL3101419 | 0.67 | GPR3 (0.93) | GPR3LIMK1MAPTALDH1A1RAB9A | |
| Dibenzothiophene SCHEMBL21121001 | 0.67 | GPR3 (0.93) | GPR3LIMK1MAPTALDH1A1RAB9A | |
| Dibenzothiophene SCHEMBL28979045 | 0.67 | GPR3 (0.93) | GPR3LIMK1MAPTALDH1A1RAB9A | |
| Dibenzothiophene SCHEMBL3101427 | 0.67 | GPR3 (0.93) | GPR3LIMK1MAPTALDH1A1RAB9A | |
| Dibenzothiophene SCHEMBL10943387 | 0.67 | GPR3 (0.93) | GPR3LIMK1MAPTALDH1A1RAB9A | |
| Dibenzothiophene SCHEMBL9934048 | 0.67 | GPR3 (0.93) | GPR3LIMK1MAPTALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981896-B2 | Pyrazoles for the treatment of obesity and other CNS disorders | ATHERSYS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20110112088-A1 | PYRAZOLES FOR THE TREATMENT OF OBESITY AND OTHER CNS DISORDERS | BENNANI YOUSSEF L | 2011-05-12 | — | — | US | disclosed |
| US-7897634-B2 | Pyrazoles for the treatment of obesity and other CNS disorders | ATHERSYS, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| EP-2152669-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | Cephalon, Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008137087-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | CEPHALON, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| US-20070197526-A1 | Pyrazoles for the treatment of obesity and other CNS disorders | ATHERSYS, INC. | 2007-08-23 | — | — | US | disclosed |
| US-4431657-A | Analgesic compositions consisting of 2H-benzothieno[3,2-c]pyrazol-3-amine derivatives | AYERST, MCKENNA & HARRISON INC. (CA) | 1984-02-14 | — | — | US | disclosed |
| US-4420476-A | Benzofuro[3,2-c]pyrazol-3-amine derivatives | Averst McKenna & Harrison, Inc. (CA) | 1983-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112088-A1 | PYRAZOLES FOR THE TREATMENT OF OBESITY AND OTHER CNS DISORDERS | GPR119, HCRTR2, HCRTR1 | GPR3 258/4885LIMK1 4389/4885CDK5 1064/4885 |
| US-20070197526-A1 | Pyrazoles for the treatment of obesity and other CNS disorders | HRH3, HRH4, HRH2 | GPR3 15/4885LIMK1 3998/4885CDK5 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.